New agents in medical oncology and the risk of venous thromboembolism

M. Manzoni, K. Bencardino, F. Piovella, S. Chatzileontiadou, S. Delfanti, A. Riccardi, Marco Danova, G. R. Corazza

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Over the past several years the medical approach to cancer patients has made important steps forward both in the field of novel, selective, antiproliferative agents and more effective supportive therapies. A greater understanding of the molecular pathways regulating cell proliferation and metastasis has led to the identification of a range of targets specifically inhibited by these new drugs. The clinical development of these compounds (the so called "targeted therapies") has shown distinctive adverse effects with respect to standard chemotherapeutic agents but the potential increasing risk of venous thromboembolism remains unvaried. In fact, the incidence of this potentially life-threatening complication in patients receiving standard chemotherapy ranges from about 11% to 20% and even more depending on the type of drug administered and on the possible association with other antineoplastic and supportive therapies. In this paper we reviewed all the available evidences concerning the increasing risk of venous thromboembolism in cancer patients during treatment with new agents currently used in medical oncology together with data concerning the clinical value of a concomitant prophylactic anticoagulation. At present, additional information concerning safety in terms of thromboembolic risk of novel biological and molecular therapies should be collected from specifically designed original basic science studies and clinical trials in order to optimize their use in current oncology practice.

Original languageEnglish
Pages (from-to)185-194
Number of pages10
JournalJournal of Experimental and Clinical Cancer Research
Volume26
Issue number2
Publication statusPublished - Jun 2007

Fingerprint

Medical Oncology
Venous Thromboembolism
Biological Therapy
Therapeutics
Pharmaceutical Preparations
Antineoplastic Agents
Neoplasms
Cell Proliferation
Clinical Trials
Neoplasm Metastasis
Safety
Drug Therapy
Incidence

Keywords

  • Chemotherapy
  • New drugs
  • Thromboembolism
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

New agents in medical oncology and the risk of venous thromboembolism. / Manzoni, M.; Bencardino, K.; Piovella, F.; Chatzileontiadou, S.; Delfanti, S.; Riccardi, A.; Danova, Marco; Corazza, G. R.

In: Journal of Experimental and Clinical Cancer Research, Vol. 26, No. 2, 06.2007, p. 185-194.

Research output: Contribution to journalArticle

Manzoni, M, Bencardino, K, Piovella, F, Chatzileontiadou, S, Delfanti, S, Riccardi, A, Danova, M & Corazza, GR 2007, 'New agents in medical oncology and the risk of venous thromboembolism', Journal of Experimental and Clinical Cancer Research, vol. 26, no. 2, pp. 185-194.
Manzoni, M. ; Bencardino, K. ; Piovella, F. ; Chatzileontiadou, S. ; Delfanti, S. ; Riccardi, A. ; Danova, Marco ; Corazza, G. R. / New agents in medical oncology and the risk of venous thromboembolism. In: Journal of Experimental and Clinical Cancer Research. 2007 ; Vol. 26, No. 2. pp. 185-194.
@article{45659a03a7534f6abbd969f489f1fd0b,
title = "New agents in medical oncology and the risk of venous thromboembolism",
abstract = "Over the past several years the medical approach to cancer patients has made important steps forward both in the field of novel, selective, antiproliferative agents and more effective supportive therapies. A greater understanding of the molecular pathways regulating cell proliferation and metastasis has led to the identification of a range of targets specifically inhibited by these new drugs. The clinical development of these compounds (the so called {"}targeted therapies{"}) has shown distinctive adverse effects with respect to standard chemotherapeutic agents but the potential increasing risk of venous thromboembolism remains unvaried. In fact, the incidence of this potentially life-threatening complication in patients receiving standard chemotherapy ranges from about 11{\%} to 20{\%} and even more depending on the type of drug administered and on the possible association with other antineoplastic and supportive therapies. In this paper we reviewed all the available evidences concerning the increasing risk of venous thromboembolism in cancer patients during treatment with new agents currently used in medical oncology together with data concerning the clinical value of a concomitant prophylactic anticoagulation. At present, additional information concerning safety in terms of thromboembolic risk of novel biological and molecular therapies should be collected from specifically designed original basic science studies and clinical trials in order to optimize their use in current oncology practice.",
keywords = "Chemotherapy, New drugs, Thromboembolism, Toxicity",
author = "M. Manzoni and K. Bencardino and F. Piovella and S. Chatzileontiadou and S. Delfanti and A. Riccardi and Marco Danova and Corazza, {G. R.}",
year = "2007",
month = "6",
language = "English",
volume = "26",
pages = "185--194",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "2",

}

TY - JOUR

T1 - New agents in medical oncology and the risk of venous thromboembolism

AU - Manzoni, M.

AU - Bencardino, K.

AU - Piovella, F.

AU - Chatzileontiadou, S.

AU - Delfanti, S.

AU - Riccardi, A.

AU - Danova, Marco

AU - Corazza, G. R.

PY - 2007/6

Y1 - 2007/6

N2 - Over the past several years the medical approach to cancer patients has made important steps forward both in the field of novel, selective, antiproliferative agents and more effective supportive therapies. A greater understanding of the molecular pathways regulating cell proliferation and metastasis has led to the identification of a range of targets specifically inhibited by these new drugs. The clinical development of these compounds (the so called "targeted therapies") has shown distinctive adverse effects with respect to standard chemotherapeutic agents but the potential increasing risk of venous thromboembolism remains unvaried. In fact, the incidence of this potentially life-threatening complication in patients receiving standard chemotherapy ranges from about 11% to 20% and even more depending on the type of drug administered and on the possible association with other antineoplastic and supportive therapies. In this paper we reviewed all the available evidences concerning the increasing risk of venous thromboembolism in cancer patients during treatment with new agents currently used in medical oncology together with data concerning the clinical value of a concomitant prophylactic anticoagulation. At present, additional information concerning safety in terms of thromboembolic risk of novel biological and molecular therapies should be collected from specifically designed original basic science studies and clinical trials in order to optimize their use in current oncology practice.

AB - Over the past several years the medical approach to cancer patients has made important steps forward both in the field of novel, selective, antiproliferative agents and more effective supportive therapies. A greater understanding of the molecular pathways regulating cell proliferation and metastasis has led to the identification of a range of targets specifically inhibited by these new drugs. The clinical development of these compounds (the so called "targeted therapies") has shown distinctive adverse effects with respect to standard chemotherapeutic agents but the potential increasing risk of venous thromboembolism remains unvaried. In fact, the incidence of this potentially life-threatening complication in patients receiving standard chemotherapy ranges from about 11% to 20% and even more depending on the type of drug administered and on the possible association with other antineoplastic and supportive therapies. In this paper we reviewed all the available evidences concerning the increasing risk of venous thromboembolism in cancer patients during treatment with new agents currently used in medical oncology together with data concerning the clinical value of a concomitant prophylactic anticoagulation. At present, additional information concerning safety in terms of thromboembolic risk of novel biological and molecular therapies should be collected from specifically designed original basic science studies and clinical trials in order to optimize their use in current oncology practice.

KW - Chemotherapy

KW - New drugs

KW - Thromboembolism

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=34347380864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347380864&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 185

EP - 194

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 2

ER -